Mesoblast Stock

Mesoblast EPS

Delisted·Jun 19, 2026

The Earnings per Share (EPS) of Mesoblast (MSB.AX) as of Aug 8, 2026 is -0.08 USD. In the previous year, Earnings per Share (EPS) was -0.09 USD — a change of -5.13% (higher).

EPS

-0.08USD

YoY

-5.13%

Last updated:

Earnings per Share (EPS) of Mesoblast is 2026 -0.08 USD. Earnings per Share (EPS) of Mesoblast was 2025 -0.09 USD. It decreases by -5.13% higher compared to the previous year.
Access this data via the Eulerpool API

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

Earnings per Share (EPS) of Mesoblast is -0.08 USD in 2026.

Earnings per Share (EPS) of Mesoblast changed from -0.09 USD to -0.08 USD, representing a -5.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Mesoblast since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

Income Statement — Mesoblast

All Key Metrics — Mesoblast